NEW YORK (GenomeWeb) – Illumina has joined the Worldwide Innovative Networking (WIN) Consortium, a network of academic, industry, not-for-profit, and insurance entities collaborating on personalized cancer care.
The WIN Consortium was founded in 2010 and its partners include France's Institut Gustave Roussy, the University of Texas MD Anderson Cancer Center, GE Healthcare, Agilent Technologies, Pfizer, AstraZeneca, Foundation Medicine, Blue Cross Blue Shield, and 25 academic centers in 17 countries. Among its initiatives is the WIN Therapeutics (WINTHER) project, which launched a couple of years ago and aims to tailor cancer treatments based on genetic analysis of patients.
John Mendelsohn, chairman of the WIN Consortium and the director of the Khalifa Institute for Personalized Cancer Therapy at MD Anderson Cancer Center, said in a statement that Illumina's "expertise will be invaluable as we work to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials, the most promising advances in genomic-based cancer research."